What the report is
- This is the 5th Annual edition of the “TGaS Digital Marketing Competency Report” by Trinity Life Sciences — the 2025 edition covers more than 150 biopharma brands. (Trinity Life Sciences)
- The methodology: Brands are ranked on a scale from “Transformational” to “Novice”, evaluated across 100+ characteristics spanning omnichannel presence, patient‑centricity, digital execution (e.g., website, search, social, direct‑to‑consumer access). (Trinity Life Sciences)
- Key metrics in this edition: A 19 % increase in brands reaching “Proficient” status compared to prior years; a 112 % increase in brands integrating Reddit into their social approach (signalling shift away from just Facebook/Instagram) among other digital innovations. (ciobulletin.com)
- The report also highlights stronger Direct‑to‑Consumer (DTC) access strategies emerging in life sciences — i.e., manufacturers engaging directly with patients/caregivers rather than purely through HCP or payer channels. (Yahoo Finance)
What was found & ranking highlights
- The companies named in the headline — GSK, Amgen and AstraZeneca — are highlighted as leaders in this 2025 ranking. (Trinity Life Sciences)
- Specific brands recognised as “Transformational” in the report include:
- Trelegy (GSK)
- Arexvy (GSK)
- Tezspire (Amgen & AstraZeneca)
- Hemlibra (Genentech)
- Mavyret (AbbVie) (Trinity Life Sciences)
- Additional top‐level insights:
- The “Proficient” category (middle‑high of maturity) saw a 19 % uplift vs previous year — indicating increasing digital maturity across the industry. (Trinity Life Sciences)
- Social channel diversification: The 112 % rise in Reddit use suggests pharma brands are exploring community‐driven, niche social channels. (ciobulletin.com)
Why this matters
- For marketers in life sciences: The study provides a benchmark of where brands stand digitally, and shows they can no longer treat digital as “adjunct” — omnichannel and patient‑centric digital engagement is now a core commercial competency.
- For the named companies:
- GSK, Amgen & AstraZeneca being flagged as leaders gives them a competitive narrative (digital first, patient engagement) that can support investor perception, brand differentiation, and internal stakeholder alignment.
- For them this recognition may translate into pressure to maintain or accelerate digital innovation lest they fall behind.
- For the broader industry:
- The average improvement (19 % increase) indicates the sector is moving forward — but also raises the bar: if you’re a brand still in “Novice” or “Emerging” you risk being left behind.
- The shift to direct‑to‑consumer and newer channels (like Reddit) signals a potential change in how pharma reaches patients – more peer/community, less classic top‑down marketing. This has implications for compliance/regulation, data governance and commercial model change.
- For agencies & suppliers: These trends highlight demand for digital capability (SEO, social beyond the usual, community building, omnichannel orchestration) and may drive service demand in life sciences marketing.
Key observations & comments
- The fact that Reddit has become a highlighted channel (112 % increase) suggests brands recognise that where patients and caregivers are congregating online is shifting — less broadcast, more community. That invites risk & reward: the risk of moderation, compliance, off‑label discussion; the reward of deeper engagement.
- The “Proficient” category’s growth (19 %) is good, but the report still implicitly suggests many brands remain in lower maturity levels. In other words: leadership is becoming differentiated, not average.
- The emphasis on “patient‑centricity” and “digital execution” rather than purely “digital marketing” signals the pivot in life sciences: from promotion of a drug → to experience / engagement over the patient lifecycle.
- For GSK, Amgen and AstraZeneca: this recognition may attract talent (digital marketers want to work for “transformational” companies), perhaps ease internal change management, but also sets expectations for delivery — i.e., ‘you’ve won recognition, now you must keep innovating’.
- The mention of Direct‑to‑Consumer (DTC) access is interesting — life sciences has typically been channelled through HCPs, payers and institutions. A shift to more DTC might raise strategic / regulatory issues — e.g., how to manage data, privacy, consent, continual engagement rather than episodic intervention.
- From a commercial strategy perspective: Digital competency becomes a competitive differentiator. If Brand A has high digital engagement and Brand B doesn’t, Brand A may gain advantage in launch, patient uptake, adherence and brand loyalty.
- For investors / analysts: This kind of ranking and the underlying shift signal that companies investing in digital capability may achieve better commercial outcomes and perhaps pricing/premium.
Things to watch & open questions
- What are the metrics behind “Transformational” vs “Proficient” vs “Novice”? The methodology summary shows more than 100 criteria, but brands may differ in how they achieve them (e.g., social innovation vs website/SEO vs omnichannel orchestration). (Trinity Life Sciences)
- Will this lead to budget shifts? If digital sophistication is rewarded, will we see more spend diverted from traditional channels to emerging digital/patient‑community channels?
- Will regulatory frameworks (especially outside the U.S.) adapt to this shift? Digital engagement, DTC access, social community work may face compliance scrutiny.
- What is the return on investment for brands flagged as “Transformational”? Are they achieving better launch uptake, higher patient retention, improved adherence, lower cost per patient? The report hints at these but the public summary doesn’t show full ROI data.
- Are smaller or niche brands able to catch up, or is the gap widening between digital “haves” and “have‑nots”? The 19 % uplift is good, but absolute maturity may still be far off for many brands.
- Here are three detailed case studies of how Trinity Life Sciences’s “5th Annual TGaS Digital Marketing Competency Report” (2025) highlights digital marketing excellence within the pharma/biotech sector — focusing on GlaxoSmithKline (GSK), Amgen Inc. and AstraZeneca PLC — followed by broader commentary and implications.
Case Study 1: GSK (GlaxoSmithKline)
Background & ranking
- GSK is recognised as one of the top‑performing companies in the 2025 report, with its brands like Trelegy and Arexvy being cited among the “Transformational” digital marketing brands. (Trinity Life Sciences)
- The report shows the overall “Proficient” tier of brands increased by 19%, indicating GSK is part of the advancing cohort. (Trinity Life Sciences)
Key digital strategy highlights
- Focus on patient‑centric digital engagement: Rather than only promoting awareness, GSK’s listed brands demonstrate deeper digital journeys (e.g., patient portals, digital resources, community hubs) as per the report’s patient‑centricity criteria.
- Use of omnichannel execution: The report evaluates “omnichannel presence, patient‑centricity, digital execution (100+ characteristics)”. GSK’s inclusion among top brands suggests strong performance across multiple channels (website, search/SEO, social, direct‑to‑consumer access) rather than isolated tactics. (Trinity Life Sciences)
- Innovation in channel strategy: The report cites a 112 % increase in use of Reddit by brands (i.e., moving beyond Facebook/Instagram) as a hallmark of digital maturity. GSK, as a top performer, is likely among those adopting newer channels. (Trinity Life Sciences)
Why this matters
- For GSK, achieving a “Transformational” rating gives a competitive advantage — internally (marketing teams can flag digital‑excellence) and externally (investors and stakeholders can view GSK as a digital frontrunner).
- It signals that GSK is likely better placed than many peers to navigate the evolving digital ecosystem (patient‑community engagement, DTC access, omnichannel measurement).
- From a commercial launch perspective, strong digital marketing maturity may accelerate uptake of new products, reinforce patient adherence, and boost brand loyalty.
Challenges / considerations
- Maintaining the lead: When you’re flagged as a top performer, expectation rises — digital execution must keep evolving. GSK must ensure its digital infrastructure, data capabilities, and measurement frameworks scale accordingly.
- Regulatory & compliance risk: With deeper patient engagement and more direct‑to‑consumer strategies (highlighted in the report), GSK must ensure adherence to privacy, health‑claims and data governance.
- Competitive pressure: As other brands increase maturity (19% lift in Proficient brands), the “lead” may narrow — GSK must continue innovating, not just maintain status quo.
Key takeaway
GSK’s strong showing in the 2025 TGaS report demonstrates that the company is well advanced in digital marketing maturity. For marketers, it sets a benchmark: it’s not enough to just have digital channels — it’s about integrated, patient‑centric journeys and newer forms of engagement.
Case Study 2: Amgen
Background & ranking
- Amgen is one of the three companies named in the headline as “leading the pack” in the 2025 report. (Trinity Life Sciences)
- Its brand partnership with AstraZeneca (for example the medication Tezspire) is cited as a “Transformational” brand in 2025. (Yahoo Finance)
Key digital strategy highlights
- Collaboration/partnership digital model: By partnering with AstraZeneca on Tezspire, Amgen demonstrates that digital marketing excellence can be a joint effort — especially when products span companies. This may include shared digital assets, co‑branded patient engagement platforms, etc.
- Direct‑to‑Consumer (DTC) access exploration: The report states leading brands are exploring DTC access strategies. As a leading brand, Amgen likely has initiatives to more directly engage patients/caregivers rather than rely solely on HCP channels. (Trinity Life Sciences)
- Channel innovation: The report emphasises expansion beyond “traditional platforms” (e.g., using Reddit, niche communities) — Amgen’s inclusion at the top suggests it is executing in those areas.
Why this matters
- Amgen’s digital maturity gives it advantage in launching, scaling and sustaining new therapies in a competitive market. With digital sophistication, Amgen can better meet changing patient expectations (more self‑service, community support, digital ecosystems).
- The partnership model (with AstraZeneca) shows that digital marketing excellence is not just company‑centric; it may be collaborative across companies and brands, especially in complex therapeutic areas.
Challenges / considerations
- Coordinating across organisations: When collaborating (Amgen + AstraZeneca), aligning digital strategy, measurement, brand governance and data systems can be complex.
- Scale of digital expectations: As Amgen is recognised among digital leaders, there’s expectation for consistent innovation — digital fatigue or under‑investment may erode advantage.
- Ensuring differentiation: With many brands improving (19% uplift in Proficient tier), Amgen must avoid complacency and keep differentiating its digital engagement model.
Key takeaway
Amgen’s recognition in the 2025 TGaS report shows the company is a benchmark for digital marketing maturity in life sciences — particularly in how it leverages partnerships, direct patient engagement and next‑gen channels.
Case Study 3: AstraZeneca
Background & ranking
- AstraZeneca is also named in the 2025 report as a leading digital marketer. (Trinity Life Sciences)
- The brand Tezspire (Amgen & AstraZeneca) is cited as Transformational. Additionally, AstraZeneca’s prior performance (e.g., Breztri in 2024) highlights consistent digital excellence. (Bastille Post)
Key digital strategy highlights
- Consistent digital positioning: AstraZeneca has been appearing at the top of these rankings for multiple years, suggesting maturity not just in isolated campaigns but in the entire digital strategy.
- Patient‑centric, omni‑channel approach: With focus on patient experience, AstraZeneca’s digital strategy likely includes multi‑channel touchpoints, digital ecosystems, community engagement and measurement.
- Use of new channels/community platforms: The report highlights a 112% increase in Reddit usage among brands; AstraZeneca being among leaders implies it is adopting such platforms. (ciobulletin.com)
Why this matters
- For AstraZeneca, being digitally advanced reinforces brand reputation as innovative — both in therapy and in engagement models. This can enhance launch success, patient adherence and brand loyalty.
- Their digital traction may help them better respond to market changes: patient expectations for digital services, virtual support, online communities etc.
Challenges / considerations
- Structural scale: Large global companies like AstraZeneca must ensure local market (regional) execution matches global strategy — digital maturity needs regional adaptation.
- Emerging channel risk: As brands pivot to new platforms (Reddit, community forums), they must monitor data/privacy/regulatory risk.
- Staying ahead: With many brands catching up (industry‑wide improvement), AstraZeneca must continue to innovate rather than rest on laurels.
Key takeaway
AstraZeneca’s consistent high ranking in the TGaS report signals digital marketing leadership in life sciences. The company sets the bar for how digital patient experience and omnichannel engagement can be leveraged in pharma.
Broader Commentary & Implications
1. The digital maturity gap is shrinking, but leaders remain distinct.
The 2025 report shows a 19% uplift in brands achieving “Proficient” rating — meaning many companies have improved. But the “Transformational” tier (where GSK, Amgen, AstraZeneca sit) remains differentiated. (ciobulletin.com)
This means: even as more companies catch up, being a digital leader still offers competitive advantage.2. Patient‑centric engagement and DTC access are non‑negotiable.
The report emphasises the shift: brands are moving beyond treatment awareness to long‑term patient relationships (wellness, digital support, behavioral change). DTC models are gaining traction. (Trinity Life Sciences)
For companies, this means investment in digital ecosystems, data platforms, and new KPIs (not just “impressions” or “HCP reach”).3. Platform diversification is critical.
The 112% increase in Reddit usage indicates a move beyond Facebook/Instagram into community‑led and niche forums. (Trinity Life Sciences)
Implication: digital strategies must account for emerging channels, moderation, community management and measurement.4. Collaboration & co‑brands matter.
Amgen & AstraZeneca’s joint brand success (Tezspire) shows that digital marketing excellence can cross organisational boundaries. Partnerships in digital (co‑branded platforms, shared ecosystems) are increasingly viable.5. For marketers and agencies:
- Benchmarking (like this TGaS report) is essential — you need to know where you stand.
- Investing in infrastructure (data, CRM, measurement), ecosystem (patient portals, community forums), and content is key.
- Capacity building: Smaller brands may struggle to catch up without dedicated digital capability.
6. For investors / executives:
Digital marketing maturity may correlate with better launch execution, stronger patient adherence, and competitive advantage — thus digital capability is increasingly a strategic asset, not just a marketing cost centre.7. Risks / Watch‑outs:
- Regulatory / privacy risk: As brands engage directly with patients and new channels, regulatory frameworks (especially for pharma) must be navigated carefully.
- ROI measurement: The report shows progress, but it doesn’t publicly provide detailed ROI data — brands must ensure they can link digital engagement to commercial outcomes.
- Saturation / diminishing returns: As more brands become proficient, standing out may become harder; innovation remains essential.